Factors associated with successful epoetin alfa therapy in premature infants

Annals of Pharmacotherapy

Volumn 34, Issue 4, 2000, Pages 433-439

  Reiter, Pamela D ^a   Rosenberg, Adam A ^a   Valuck, Robert J ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Epoetin alfa; Erythropoietin; Premature infants; Red blood cell transfusions

Indexed keywords

IRON; RECOMBINANT ERYTHROPOIETIN;

AGE; ANEMIA; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CORRELATION FUNCTION; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; HEMATOCRIT; HUMAN; INFANT; IRON THERAPY; NEWBORN; PREMATURITY; PRIORITY JOURNAL; RETICULOCYTE COUNT; TREATMENT OUTCOME;

ANEMIA, NEONATAL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOETIN ALFA; ERYTHROCYTE TRANSFUSION; HEMATINICS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; IRON; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0034081650     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19169     Document Type: Article

References (18)

1. Halperin DS, Felix M, Lacourt G, Babel JF, Wyss M. Recombinant human erythropoietin in the treatment of infants with anaemia of prematurity. Eur J Pediatr 1992;151:661-7.
2. Shannon KM, Mentzer WC, Abels RI, Freeman P, Newton N, Thompson D, et al. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo-controlled pilot study. J Pediatr 1991;118:949-55.
3. Meyer MP, Meyer JH, Commerford A, Hann FM, Sive AA, Moller G, et al. Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double-blind, placebo-controlled study. Pediatrics 1994;93:918-23.
4. Carnielli V, Montini G, Da Riol R, Dall'Amico R, Cantarutti F. Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. J Pediatr 1992;121:98-102.
5. Maier RF, Obladen M, Kattner E, Natzschka J, Messer J, Regazzoni BM, et al. High-versus low-dose erythropoietin in extremely low birth weight infants. The European Multicenter rhEPO Study Group. J Pediatr 1998;132:866-70.
6. Ohls RK, Harcum J, Schibler KR, Christensen RD. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double-blind, placebo-controlled study. J Pediatr 1997;131:661-5.
7. Messer J, Haddad J, Donato L, Astruc D, Matis J. Early treatment of premature infants with recombinant human erythropoietin. Pediatrics 1993; 92:519-23.
8. Widness JA, Veng-Pedersen P, Peters C, Pereira LM, Schmidt RL, Lowe LS. Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects. J Appl Physiol 1996;80: 140-8.
9. Soubasi V, Kremenopoulos K, Diamandi E, Tsantali C, Tsakiris D. In which neonates does early recombinant human erythropoietin treatment prevent anemia of premarurity? Results of a randomized, controlled study. Pediatr Res 1993;34:675-9.
10. Bechensteen AG, Haga P, Halvorsen S, Liestrol K, Lindemann R, Whitelaw A, et al. Effect of low and moderate doses of recombinant human erythropoietin on the haematological response in premature infants on a high protein and iron intake. Eur J Pediatr 1997;156:56-61.
11. Wandstrant TL, Kaplan B. Use of erythropoietin in premature neonates: controversies and the future. Ann Pharmacother 1995;29:166-73.
12. Kumar P, Shankaran S, Krishnan RG. Recombinant human erythropoietin therapy for treatment of anemia of prematurity in very low birth weight infants: a randomized, double-blind, placebo-controlled trial. J Perinatol 1998;18:173-7.
13. Ohls RK, Veerman MW, Christensen RD. Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solutions. J Pediatr 1996;128:518-23.
14. Ohls RK, Christensen RD. Stability of human recombinant epoetin alfa in commonly used neonatal intravenous solutions. Ann Pharmacother 1996;30:466-8.
15. Meyer MP, Haworth C, McNeill L. Is the use of recombinant human erythropoietin in anemia of prematurity cost-effective? S Afr Med J 1996;86:251-3.
16. Ohls RK, Osborne KA, Christensen RD. Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo-controlled trial. J Pediatr 1995;126:421-6.
17. Meyer MP. Anemia of prematurity. Epidemiology, management and costs. Pharmacoeconomics 1997;12:438-45.
18. Data on file. Raritan, NJ: Ortho Biotech, 08869-0670.